On the other hand, the CML+apoA-I and CML+CIGB-258 groups showed comparable survivability (~70–80% and 65–70% at 1 h and 3 h post-injection, respectively), suggesting that apoA-I and CIGB-258 had adequate anti-inflammatory activity, to a similar extent. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.